主要文件

查看所有文档

A5605

苯磺酸氨氯地平

Name: 苯磺酸氨氯地平
Brand: SIGMA

≥98% (HPLC), L-type calcium channel blocker, powder

别名:

2-[(2-氨基乙氧基)-甲基]-4-(2-氯苯基)-1,4-二氢-6-甲基-3,5-吡啶二甲酸 3-乙基 5-甲酯苯磺酸酯, 活络喜(抗高血压药)

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₀H₂₅ClN₂O₅ · C₆H₅SO₃H

化学文摘社编号:

111470-99-6

分子量:

567.05

UNSPSC Code:

12352200

PubChem Substance ID:

24890999

NACRES:

NA.77

MDL number:

MFCD00887594

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

苯磺酸氨氯地平, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white

solubility

DMSO: ≥20 mg/mL

SMILES string

OS(=O)(=O)c1ccccc1.CCOC(=O)C2=C(COCCN)NC(C)=C(C2c3ccccc3Cl)C(=O)OC

InChI

1S/C20H25ClN2O5.C6H6O3S/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21;7-10(8,9)6-4-2-1-3-5-6/h5-8,17,23H,4,9-11,22H2,1-3H3;1-5H,(H,7,8,9)

InChI key

ZPBWCRDSRKPIDG-UHFFFAOYSA-N

Gene Information

human ... CACNA1C(775), CACNA1D(776), CACNA1F(778), CACNA1S(779)

说明

Application

苯磺酸氨氯地平是一种 L 型钙通道阻滞剂，可用于治疗心绞痛和高血压。氨氯地平还可抑制人表皮样癌细胞 A431 的生长，并对雄性大鼠具有抗生殖作用。

Biochem/physiol Actions

氨氯地平是一种 L 型钙通道阻滞剂。氨氯地平属于一类心血管药物，作用于 Ca _V 1 或 L 型的电压门控钙通道。氨氯地平还具有降压和抗心绞痛作用。其活性主要存在于 (-)-异构体中。氨氯地平抑制人表皮样癌细胞 A431 的生长，对雄性大鼠有抗生殖作用。

苯磺酸氨氯地平是一种 L 型钙通道阻滞剂。

Features and Benefits

该化合物在受体分类和信号转导手册的钙通道页面上有重点介绍。如需浏览其他手册页面，请点击此处。

Still not finding the right product?

Explore all of our products under 苯磺酸氨氯地平

pictograms

GHS07

signalword

Warning

hcodes

H302

pcodes

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

商品

钙通道

我们提供多种与钙通道相关的产品以满足您的各类研究需求。

Calcium Channels

We offers many products related to calcium channels for your research needs.

Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension.

Dean J Kereiakes et al.

Journal of clinical hypertension (Greenwich, Conn.), 14(3), 149-157 (2012-03-01)

J Clin Hypertens (Greenwich). 2012;14:149-157. ©2012 Wiley Periodicals, Inc. Most patients with hypertension require combination therapy in order to achieve blood pressure (BP) goals. This 40-week open-label extension of the 12-week double-blind Triple Therapy With Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide

Reduced Lymphatic Function Predisposes to Calcium Channel Blocker Edema: A Randomized Placebo-Controlled Clinical Trial.

Sheyanth Mohanakumar et al.

Lymphatic research and biology, 18(2), 156-165 (2019-08-21)

Background: The current belief is that the calcium channel blocker (CCB)-induced edema is due to a preferential arterial over

Amlodipine reduces cardiac iron overload in patients with thalassemia major: a pilot trial.

Juliano Lara Fernandes et al.

The American journal of medicine, 126(9), 834-837 (2013-07-09)

Iron chelation therapy in patients with thalassemia major may not prevent iron overload in all organs, especially those in which iron enters cells through specific calcium channels. We designed a controlled pilot study to assess the potential of the calcium

查看所有相关文献

全球贸易项目编号

货号	GTIN
A5605-10MG	04061833376102
A5605-50MG	04061833376119